Current Immunotherapy: Progress With Adoptive Cellular Therapies and Combinations

Source: Targeted Oncology, February 2020

The clinical development and application of cancer immunotherapy over the past decade has translated the long-standing knowledge of the close relationship between cancerous tissues and lymphoid immune cells, dating back to the late 19th century.1,2 Today, cancer immunotherapies, all of which recruit the body’s own immune system to target and eliminate cancer cells, represent a rapidly expanding and paradigm-shifting arsenal in cancer treatment. Immunotherapies that have gained regulatory approval and/or are in clinical development include immune checkpoint blockade agents, chimeric antigen receptor (CAR) T-cell therapy, cancer vaccines, and adoptive or engineered T cell–based therapies (FIGURE 1).3–5

 

Read the original full article